[go: up one dir, main page]

GB2211504B - Fowlpox virus promoters - Google Patents

Fowlpox virus promoters

Info

Publication number
GB2211504B
GB2211504B GB8824746A GB8824746A GB2211504B GB 2211504 B GB2211504 B GB 2211504B GB 8824746 A GB8824746 A GB 8824746A GB 8824746 A GB8824746 A GB 8824746A GB 2211504 B GB2211504 B GB 2211504B
Authority
GB
United Kingdom
Prior art keywords
fowlpox virus
virus promoters
promoters
fowlpox
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
GB8824746A
Other versions
GB2211504A (en
GB8824746D0 (en
Inventor
Matthew Mckinley Binns
Michael Edward Griff Boursnell
Joan Iyabo Amiemenogh Campbell
Fiona Margaret Tomley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NAT RES DEV
National Research Development Corp UK
Original Assignee
NAT RES DEV
National Research Development Corp UK
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by NAT RES DEV, National Research Development Corp UK filed Critical NAT RES DEV
Publication of GB8824746D0 publication Critical patent/GB8824746D0/en
Publication of GB2211504A publication Critical patent/GB2211504A/en
Priority to CA002001001A priority Critical patent/CA2001001A1/en
Priority to PT92059A priority patent/PT92059B/en
Priority to PCT/GB1989/001257 priority patent/WO1990004638A1/en
Priority to US07/669,404 priority patent/US5374558A/en
Priority to JP1511386A priority patent/JPH03505403A/en
Priority to EP89310821A priority patent/EP0365349A1/en
Priority to GB8923652A priority patent/GB2224736B/en
Priority to AU44909/89A priority patent/AU638219B2/en
Priority to ZA897965A priority patent/ZA897965B/en
Application granted granted Critical
Publication of GB2211504B publication Critical patent/GB2211504B/en
Priority to DK072291A priority patent/DK72291A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
GB8824746A 1987-10-23 1988-11-09 Fowlpox virus promoters Expired - Lifetime GB2211504B (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
CA002001001A CA2001001A1 (en) 1988-10-21 1989-10-19 Fowlpox virus promoter
ZA897965A ZA897965B (en) 1988-11-09 1989-10-20 Fowlpox virus promoter
PT92059A PT92059B (en) 1988-11-09 1989-10-20 PROCESS FOR THE PREPARATION OF A PROMOTER OF VIRIOLA VIRUSES OF DOMESTIC BIRDS
PCT/GB1989/001257 WO1990004638A1 (en) 1988-10-21 1989-10-20 Fowlpox virus promoter
US07/669,404 US5374558A (en) 1988-10-21 1989-10-20 Fowlpox virus promoter
JP1511386A JPH03505403A (en) 1988-10-21 1989-10-20 chicken pox virus promoter
EP89310821A EP0365349A1 (en) 1988-10-21 1989-10-20 Avipox virus promoter
GB8923652A GB2224736B (en) 1988-11-09 1989-10-20 Avipox virus promoter
AU44909/89A AU638219B2 (en) 1988-10-21 1989-10-20 Fowlpox virus promoter
DK072291A DK72291A (en) 1988-11-09 1991-04-19 POULTRY CUP VIRUS PROMOTER

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB878724885A GB8724885D0 (en) 1987-10-23 1987-10-23 Fowlpox virus promotors

Publications (3)

Publication Number Publication Date
GB8824746D0 GB8824746D0 (en) 1988-11-30
GB2211504A GB2211504A (en) 1989-07-05
GB2211504B true GB2211504B (en) 1991-01-30

Family

ID=10625792

Family Applications (2)

Application Number Title Priority Date Filing Date
GB878724885A Pending GB8724885D0 (en) 1987-10-23 1987-10-23 Fowlpox virus promotors
GB8824746A Expired - Lifetime GB2211504B (en) 1987-10-23 1988-11-09 Fowlpox virus promoters

Family Applications Before (1)

Application Number Title Priority Date Filing Date
GB878724885A Pending GB8724885D0 (en) 1987-10-23 1987-10-23 Fowlpox virus promotors

Country Status (7)

Country Link
US (1) US5182210A (en)
EP (1) EP0389509B1 (en)
JP (1) JPH03500604A (en)
AU (1) AU613291B2 (en)
DE (1) DE3882144T2 (en)
GB (2) GB8724885D0 (en)
WO (1) WO1989003879A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7553831B2 (en) 2000-06-30 2009-06-30 Elan Pharmaceuticals, Inc. Compounds to treat Alzheimer's disease

Families Citing this family (180)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5833975A (en) * 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
US7767449B1 (en) 1981-12-24 2010-08-03 Health Research Incorporated Methods using modified vaccinia virus
US5174993A (en) * 1981-12-24 1992-12-29 Health Research Inc. Recombinant avipox virus and immunological use thereof
DE10399031I1 (en) * 1987-08-28 2004-01-29 Health Research Inc Recombinant viruses.
US5093258A (en) * 1988-08-26 1992-03-03 Therion Biologics Corporation Recombinant fowlpox virus and recombination vector
CA2001001A1 (en) * 1988-10-21 1990-04-21 Matthew M. Binns Fowlpox virus promoter
GB8917059D0 (en) * 1989-07-26 1989-09-13 Nat Res Dev Avipox virus promoters
DE4002521A1 (en) * 1990-01-29 1991-08-01 Immuno Ag Recombinant plasmids for pox virus transformation - contg. multifunctional DNA sequence cassette to facilitate cloning of foreign DNA
CA2156423A1 (en) * 1993-02-26 1994-09-01 Mark D. Cochran Recombinant fowlpox viruses and uses thereof
US6136318A (en) * 1993-02-26 2000-10-24 Cochran; Mark D. Recombinant fowlpox viruses and uses thereof
US5925358A (en) * 1993-02-26 1999-07-20 Syntro Corporation Recombinant fowlpox viruses and uses thereof
US6984728B2 (en) 1993-09-24 2006-01-10 Schering Corporation Recombinant infectious laryngotracheitis virus and uses thereof
WO1995008622A1 (en) * 1993-09-24 1995-03-30 Syntro Corporation Recombinant infectious laryngotracheitis virus and uses thereof
US5877016A (en) 1994-03-18 1999-03-02 Genentech, Inc. Human trk receptors and neurotrophic factor inhibitors
US5708142A (en) 1994-05-27 1998-01-13 Genentech, Inc. Tumor necrosis factor receptor-associated factors
US6998116B1 (en) 1996-01-09 2006-02-14 Genentech, Inc. Apo-2 ligand
US6030945A (en) * 1996-01-09 2000-02-29 Genentech, Inc. Apo-2 ligand
JP2000507829A (en) 1996-04-01 2000-06-27 ジェネンテック インコーポレーテッド APO-2LI and APO-3 apoptotic polypeptide
US5851984A (en) * 1996-08-16 1998-12-22 Genentech, Inc. Method of enhancing proliferation or differentiation of hematopoietic stem cells using Wnt polypeptides
US6159462A (en) * 1996-08-16 2000-12-12 Genentech, Inc. Uses of Wnt polypeptides
US6462176B1 (en) 1996-09-23 2002-10-08 Genentech, Inc. Apo-3 polypeptide
US5990281A (en) * 1996-09-30 1999-11-23 Genentech, Inc. Vertebrate smoothened proteins
US6100076A (en) 1997-01-31 2000-08-08 Genentech, Inc. O-fucosyltransferase
WO1998033924A1 (en) 1997-01-31 1998-08-06 Genentech, Inc. O-fucosyltransferase
WO1999047677A2 (en) 1998-03-17 1999-09-23 Genentech, Inc. Polypeptides homologous to vegf and bmp1
WO2000039297A2 (en) 1998-12-23 2000-07-06 Genentech, Inc. Il-1 related polypeptides
US6342369B1 (en) 1997-05-15 2002-01-29 Genentech, Inc. Apo-2-receptor
JP2001523977A (en) 1997-06-05 2001-11-27 ザ ユニバーシティ オブ テキサス システム ボード オブ リージェンツ Activator of APAF-1, CED-4 human homolog, caspase-3
AU740227B2 (en) 1997-06-18 2001-11-01 Genentech Inc. Apo-2DcR
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
DK1015587T3 (en) 1997-09-18 2008-08-25 Genentech Inc DcR3 polypeptide, a TNFR homolog
IL135051A0 (en) 1997-10-10 2001-05-20 Genentech Inc Apo-3 ligand polypeptide
AU1288399A (en) 1997-10-29 1999-05-17 Genentech Inc. Wnt-1 induced secreted polypeptides: wisp-1, -2 and -3
DE69840051D1 (en) 1997-10-29 2008-11-06 Genentech Inc BY WNT-1 INDUCIBLE GENE
US7192589B2 (en) 1998-09-16 2007-03-20 Genentech, Inc. Treatment of inflammatory disorders with STIgMA immunoadhesins
ES2316175T3 (en) 1997-11-21 2009-04-01 Genentech, Inc. SPECIFIC ANTIGENS OF PLATQUETS AND THEIR PHARMACOLOGICAL USES.
ES2316182T3 (en) 1998-01-15 2009-04-01 Genentech, Inc. BINDING APO-2.
US6727079B1 (en) 1998-02-25 2004-04-27 The United States Of America As Represented By The Department Of Health And Human Services cDNA encoding a gene BOG (B5T Over-expressed Gene) and its protein product
EP2050762A3 (en) 1998-03-10 2009-07-08 Genentech, Inc. Human cornichon-like protein and nucleic acids encoding it
AU740405B2 (en) 1998-05-15 2001-11-01 Genentech Inc. IL-17 homologous polypeptides and therapeutic uses thereof
EP1865061A3 (en) 1998-05-15 2007-12-19 Genentech, Inc. IL-17 homologous polypeptides and therapeutic uses thereof
US20020172678A1 (en) 2000-06-23 2002-11-21 Napoleone Ferrara EG-VEGF nucleic acids and polypeptides and methods of use
CA2450402A1 (en) 1998-12-22 2000-06-29 Genentech, Inc. Methods and compositions for inhibiting cancer cell growth comprising pro224
EP1792989A1 (en) 1999-04-12 2007-06-06 Agensys, Inc. 13 Transmembrane protein expressed in prostate cancer
WO2000073479A1 (en) 1999-05-28 2000-12-07 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services A combined growth factor-deleted and thymidine kinase-deleted vaccinia virus vector
EP1956030B1 (en) 1999-06-15 2009-11-11 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids endoding the same
CA2380550C (en) 1999-08-12 2011-02-01 Urogenesys, Inc. C type lectin transmembrane antigen expressed in human prostate cancer and uses thereof
DE60041073D1 (en) 1999-10-05 2009-01-22 Agensys Inc G PROTEIN-COUPLED RECEPTOR HIGHLY EXPRESSED IN PROSTATE CANCER AND ITS USES
US6790631B1 (en) 1999-10-05 2004-09-14 Agensys, Inc. G protein-coupled receptor up-regulated in prostate cancer and uses thereof
US7361338B2 (en) 1999-10-05 2008-04-22 Agensys, Inc. Methods to inhibit growth of prostate cancer cells
EP1690872A3 (en) 1999-12-01 2006-08-23 Genentech, Inc. Composition and methods for the diagnosis of tumours
EP1897943B1 (en) 1999-12-23 2011-12-14 Genentech, Inc. IL-17 homologous polypeptides and therapeutic uses thereof
DE60144204D1 (en) 2000-01-26 2011-04-21 Agensys Inc 84P2A9: Prostate and testicular protein that is very common in prostate cancer
DE60124080T2 (en) 2000-03-23 2007-03-01 Elan Pharmaceuticals, Inc., San Francisco COMPOUNDS AND METHOD FOR THE TREATMENT OF ALZHEIMER'S DISEASE
DK1266018T3 (en) 2000-03-24 2008-09-01 Genencor Int Preparation of secreted proteins by recombinant eukaryotic cells
EP2042597B1 (en) 2000-06-23 2014-05-07 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogenesis
EP2168980A1 (en) 2000-06-23 2010-03-31 Genentech, Inc. Compositions and methods for the diagnosis and treatment of disorders involving angiogensis
PE20020276A1 (en) 2000-06-30 2002-04-06 Elan Pharm Inc SUBSTITUTE AMINE COMPOUNDS AS ß-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER
MXPA02012560A (en) 2000-06-30 2003-05-14 Elan Pharm Inc Compounds to treat alzheimer s disease.
DE60136281D1 (en) 2000-08-24 2008-12-04 Genentech Inc METHOD FOR INHIBITING IL-22-INDUCED PAP1
CA2705366A1 (en) 2000-08-28 2002-03-07 Agensys, Inc. Nucleic acid and corresponding protein entitled 85p1b3 useful in treatment and detection of cancer
EP1944317A3 (en) 2000-09-01 2008-09-17 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
US6673580B2 (en) 2000-10-27 2004-01-06 Genentech, Inc. Identification and modification of immunodominant epitopes in polypeptides
US6924358B2 (en) 2001-03-05 2005-08-02 Agensys, Inc. 121P1F1: a tissue specific protein highly expressed in various cancers
US8647826B2 (en) 2001-03-14 2014-02-11 Agensys, Inc. Nucleic acid and corresponding protein entitled 125P5C8 useful in treatment and detection of cancer
US7271240B2 (en) 2001-03-14 2007-09-18 Agensys, Inc. 125P5C8: a tissue specific protein highly expressed in various cancers
US20030191073A1 (en) 2001-11-07 2003-10-09 Challita-Eid Pia M. Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer
WO2002083921A2 (en) 2001-04-10 2002-10-24 Agensys, Inc. Nuleic acids and corresponding proteins useful in the detection and treatment of various cancers
US20070160576A1 (en) 2001-06-05 2007-07-12 Genentech, Inc. IL-17A/F heterologous polypeptides and therapeutic uses thereof
KR100788092B1 (en) 2001-06-20 2007-12-21 제넨테크, 인크. Compositions and Methods for the Diagnosis and Treatment of Tumor
US6982264B2 (en) 2001-06-27 2006-01-03 Elan Pharmaceuticals, Inc. Substituted alcohols useful in treatment of Alzheimer's disease
SI1427830T1 (en) 2001-08-29 2012-08-31 Genentech Inc Bv8 NUCLEIC ACIDS AND POLYPEPTIDES WITH MITOGENIC ACTIVITY
EP1429793B1 (en) 2001-09-06 2015-02-25 Agensys, Inc. Nucleic acid and corresponding protein entitled steap-1 useful in treatment and detection of cancer
EP2143438B1 (en) 2001-09-18 2011-07-13 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumors
EP2067472A1 (en) 2002-01-02 2009-06-10 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
JP2005535290A (en) 2002-02-22 2005-11-24 ジェネンテック・インコーポレーテッド Compositions and methods for the treatment of immune related diseases
AU2003230874A1 (en) 2002-04-16 2003-11-03 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP2305710A3 (en) 2002-06-03 2013-05-29 Genentech, Inc. Synthetic antibody phage libraries
WO2003103725A1 (en) 2002-06-07 2003-12-18 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
AU2003247806B2 (en) 2002-07-08 2009-11-12 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US20040081653A1 (en) 2002-08-16 2004-04-29 Raitano Arthur B. Nucleic acids and corresponding proteins entitled 251P5G2 useful in treatment and detection of cancer
CA2497334A1 (en) 2002-09-11 2004-03-25 Genentech, Inc. Novel compositions and methods for the treatment of immune related diseases
EP2277532A1 (en) 2002-09-11 2011-01-26 Genentech, Inc. Novel composition and methods for the treatment of immune related diseases
AU2003291625B2 (en) 2002-09-16 2009-10-08 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
EP2500438A3 (en) 2002-09-25 2012-11-28 Genentech, Inc. Novel compositions and methods for the treatment of psoriasis
JP2006517785A (en) 2002-10-29 2006-08-03 ジェネンテック・インコーポレーテッド Novel compositions and methods for the treatment of immune related diseases
EP1581169A4 (en) 2002-11-08 2008-09-17 Genentech Inc COMPOSITIONS AND METHODS FOR TREATING DISEASES RELATED TO NATURAL K CELLS
JP2011516026A (en) 2002-11-26 2011-05-26 ジェネンテック・インコーポレーテッド Compositions and methods for the treatment of immune related diseases
EP1594892A2 (en) 2003-02-10 2005-11-16 Agensys, Inc. Nucleic acid and corresponding protein named 158p1d7 useful in the treatment and detection of bladder and other cancers
EP2526960A1 (en) 2003-03-12 2012-11-28 Genentech, Inc. Use of BV8 and/or EG-VEGF to promote hematopoiesis
PL1610820T5 (en) 2003-04-04 2014-01-31 Genentech Inc High concentration antibody and protein formulations
MXPA05012957A (en) 2003-05-30 2006-06-27 Agensys Inc Prostate stem cell antigen (psca) variants and subsequences thereof.
ES2751414T5 (en) 2003-07-08 2024-04-23 Novartis Pharma Ag Antagonist antibodies to heterologous IL-17 A/F polypeptides
WO2005019258A2 (en) 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
DK2161283T3 (en) 2003-11-17 2014-09-01 Genentech Inc COMPOSITIONS CONTAINING ANTIBODIES AGAINST CD79b CONJUGED TO A GROWTH INHIBITOR OR CYTOTOXIC AGENT, AND METHODS FOR TREATING TUMOR OF HEMATOPOIETIC ORIGIN
AU2005250370B2 (en) 2004-05-28 2010-04-01 Agensys, Inc. Antibodies and related molecules that bind to PSCA proteins
WO2006105488A2 (en) 2005-03-31 2006-10-05 Agensys, Inc. Antibodies and related molecules that bind to 161p2f10b proteins
EP1871163A2 (en) 2005-06-06 2008-01-02 Genentech, Inc. Transgenic models for different genes and their use for gene characterization
EP1995321A2 (en) 2005-08-15 2008-11-26 Genentech, Inc. Gene disruptions, compositions and methods relating thereto
EP2002714A1 (en) 2005-11-21 2008-12-17 Genentech, Inc. Novel gene disruptions, compositions and methods relating thereto
ZA200807714B (en) 2006-02-17 2010-01-27 Genentech Inc Gene disruptions, compositions and methods relating thereto
CA2644663A1 (en) 2006-03-23 2007-09-27 Kirin Pharma Kabushiki Kaisha Agonist antibody to human thrombopoietin receptor
AU2007243946B2 (en) 2006-04-05 2012-11-29 Curis, Inc. Method for using BOC/CDO to modulate hedgehog signaling
AU2007297565A1 (en) 2006-04-19 2008-03-27 Genentech, Inc. Novel gene disruptions, compositions and methods relating thereto
US8592149B2 (en) 2006-04-27 2013-11-26 Pikamab, Inc. Methods and compositions for antibody therapy
WO2007131133A2 (en) 2006-05-04 2007-11-15 Genentech, Inc. Methods and compositions relating to zpa polypeptides
NZ576445A (en) 2006-11-02 2012-03-30 Daniel J Capon Hybrid immunoglobulins with moving parts
CA2676790A1 (en) 2007-02-22 2008-08-28 Genentech, Inc. Methods for detecting inflammatory bowel disease
WO2009012256A1 (en) 2007-07-16 2009-01-22 Genentech, Inc. Humanized anti-cd79b antibodies and immunoconjugates and methods of use
DK2176296T3 (en) 2007-07-16 2012-05-21 Genentech Inc Anti-CD79B antibodies and immune conjugates and methods of use.
US20090233990A1 (en) 2007-11-01 2009-09-17 Hee Cheol Cho Generation of biological pacemaker activity
EP2222700A2 (en) 2007-11-27 2010-09-01 Medtronic, Inc. Humanized anti-amyloid beta antibodies
DK2247620T3 (en) 2008-01-31 2016-08-22 Genentech Inc ANTI-CD79b ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE
HUE036780T2 (en) 2008-04-09 2018-07-30 Genentech Inc New compositions and methods for treating immunologically related diseases
US9702877B2 (en) 2008-10-31 2017-07-11 Quest Diagnostics Investments Incorporated BCR-ABL variants
CN102471380B (en) 2009-04-01 2015-01-14 霍夫曼-拉罗奇有限公司 Anti-fcrh5 antibodies and immunoconjugates and methods of use
WO2011041308A1 (en) 2009-09-30 2011-04-07 Quest Diagnostics Investments Incorporated Bcr-abl truncation mutations
EP2488643A4 (en) 2009-10-15 2013-07-03 Hoffmann La Roche CHIMERIC FIBROBLAST GROWTH FACTORS WITH MODIFIED RECEPTOR SPECIFICITY
WO2011050194A1 (en) 2009-10-22 2011-04-28 Genentech, Inc. Methods and compositions for modulating hepsin activation of macrophage-stimulating protein
WO2011056502A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Bone morphogenetic protein receptor type ii compositions and methods of use
WO2011056494A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor-like kinase-1 antagonist and vegfr3 antagonist combinations
WO2011056497A1 (en) 2009-10-26 2011-05-12 Genentech, Inc. Activin receptor type iib compositions and methods of use
KR20120103587A (en) 2009-11-12 2012-09-19 제넨테크, 인크. A method of promoting dendritic spine density
CN102741294A (en) 2009-11-30 2012-10-17 霍夫曼-拉罗奇有限公司 Antibodies for the treatment and diagnosis of tumors expressing SLC34A2 (TAT211=SEQID2)
WO2011071957A1 (en) 2009-12-07 2011-06-16 Sea Lane Biotechnologies, Llc Conjugates comprising an antibody surrogate scaffold with improved pharmacokinetic properties
WO2011106297A2 (en) 2010-02-23 2011-09-01 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
AU2011248354A1 (en) 2010-05-03 2012-11-08 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
WO2011149461A1 (en) 2010-05-27 2011-12-01 Medtronic, Inc. Anti-amyloid beta antibodies conjugated to sialic acid-containing molecules
US20130150286A1 (en) 2010-06-25 2013-06-13 Jean-Claude Sirard Methods and pharmaceutical compositions for the treatment of respiratory tract infections
CN102380091A (en) 2010-08-31 2012-03-21 健能隆医药技术（上海）有限公司 Application of interleukin-22 in curing virus hepatitis
CA2811403A1 (en) 2010-09-15 2012-03-22 Aligna Technologies, Inc. Bioproduction of aromatic chemicals from lignin-derived compounds
US8603740B2 (en) 2010-12-29 2013-12-10 Quest Diagnostics Investments Incorporated BCR-ABL1 splice variants and uses thereof
US9550818B2 (en) 2012-04-27 2017-01-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods for use of vascular endothelial growth factor antagonists
EP3611180B1 (en) 2013-03-15 2021-12-22 Biomolecular Holdings LLC Hybrid immunoglobulin containing non-peptidyl linkage
AU2014233494B2 (en) 2013-03-15 2018-10-04 Genentech, Inc. IL-22 polypeptides and IL-22 Fc fusion proteins and methods of use
WO2014182972A2 (en) 2013-05-10 2014-11-13 The Regents Of The University Of California Diagnostic and monitoring system for huntington's disease
WO2015116902A1 (en) 2014-01-31 2015-08-06 Genentech, Inc. G-protein coupled receptors in hedgehog signaling
SG10201807877TA (en) 2014-03-14 2018-10-30 Daniel Capon Hybrid immunoglobulin containing non-peptidyl linkage
CN106413739B (en) 2014-12-09 2019-09-17 张文涛 NBP158 and its uses
US10881102B2 (en) 2015-05-18 2021-01-05 Zymtronix, Llc Magnetically immobilized microbiocidal enzymes
CN108140848B (en) 2015-07-15 2022-02-01 齐姆特罗尼克斯公司 Automated biological nanocatalyst production
WO2018034877A1 (en) 2016-08-13 2018-02-22 Zymtronix, Llc Magnetically immobilized biocidal enzymes and biocidal chemicals
CA3049766A1 (en) 2017-01-13 2018-07-19 The Regents Of The University Of California Immunoengineered pluripotent cells
WO2018152496A1 (en) 2017-02-17 2018-08-23 The Usa, As Represented By The Secretary, Dept. Of Health And Human Services Compositions and methods for the diagnosis and treatment of zika virus infection
EP4230649A3 (en) 2017-04-25 2023-10-25 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Antibodies and methods for the diagnosis and treatment of epstein barr virus infection
EP3655430A1 (en) 2017-07-19 2020-05-27 The U.S.A. as represented by the Secretary, Department of Health and Human Services Antibodies and methods for the diagnosis and treatment of hepatitis b virus infection
EP3676378A4 (en) 2017-08-31 2021-06-09 The New York Genome Center METHODS AND COMPOSITIONS INCLUDING CRISPR-CPF1 AND PAIRED CRISPR GUIDANCE RNAs FOR PROGRAMMABLE GENOMIC DELETIONS
LT3743088T (en) 2018-01-26 2022-12-27 F. Hoffmann-La Roche Ag Il-22 fc compositions and methods of use
AU2019212709A1 (en) 2018-01-26 2020-08-13 Genentech, Inc. IL-22 Fc fusion proteins and methods of use
EP3755364A1 (en) 2018-02-21 2020-12-30 F. Hoffmann-La Roche AG Dosing for treatment with il-22 fc fusion proteins
US12084489B2 (en) 2018-05-02 2024-09-10 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibodies and methods for the diagnosis, prevention, and treatment of Epstein Barr virus infection
US20210263001A1 (en) 2018-09-05 2021-08-26 Zymtronix Catalytic Systems, Inc. Immobilized enzymes and microsomes on magnetic scaffolds
US11162079B2 (en) 2019-05-10 2021-11-02 The Regents Of The University Of California Blood type O Rh-hypo-immunogenic pluripotent cells
MX2021013713A (en) 2019-05-10 2021-12-10 Univ California MODIFIED PLURIPOTENT CELLS.
AU2020307550A1 (en) 2019-06-26 2022-02-03 The Regents Of The University Of California SIRPalpha-silenced natural killer (NK) cells
JP2022543112A (en) 2019-08-01 2022-10-07 サナ バイオテクノロジー，インコーポレイテッド DUX4-expressing cells and their uses
US20230025289A1 (en) 2019-08-23 2023-01-26 Sana Biotechnology, Inc. Cd24 expressing cells and uses thereof
WO2021146222A1 (en) 2020-01-13 2021-07-22 Sana Biotechnology, Inc. Modification of blood type antigens
EP4585223A3 (en) 2020-01-15 2025-07-30 The Regents of the University of California Transplanted cell protection via inhibition of polymorphonuclear cells
EP4090747A1 (en) 2020-01-17 2022-11-23 Sana Biotechnology, Inc. Safety switches for regulation of gene expression
KR20220158046A (en) 2020-03-25 2022-11-29 사나 바이오테크놀로지, 인크. Immunocompromised Neuronal Cells for Treatment of Nervous System Disorders and Conditions
WO2021207662A1 (en) 2020-04-10 2021-10-14 Genentech, Inc. Use of il-22fc for the treatment or prevention of pneumonia, acute respiratory distress syndrome, or cytokine release syndrome
CA3177517A1 (en) 2020-05-06 2021-11-11 Ernest S. Smith Integral membrane protein display on poxvirus extracellular enveloped virions
MX2023001831A (en) 2020-08-13 2023-06-29 Sana Biotechnology Inc METHODS OF TREATMENT OF SENSITIZED PATIENTS WITH HYPOIMMUNOGENIC CELLS AND ASSOCIATED METHODS AND COMPOSITIONS.
MX2023006207A (en) 2020-12-31 2023-08-09 Sana Biotechnology Inc Methods and compositions for modulating car-t activity.
US20240252642A1 (en) 2021-05-19 2024-08-01 Sana Biotechnology, Inc. Hypoimmunogenic rhd negative primary t cells
JP2024521619A (en) 2021-05-27 2024-06-04 サナ バイオテクノロジー，インコーポレイテッド Hypoimmunogenic cells containing engineered HLA-E or HLA-G
US20240316198A1 (en) 2021-07-14 2024-09-26 Sana Biotechnology, Inc. Altered expression of y chromosome-linked antigens in hypoimmunogenic cells
EP4384189A1 (en) 2021-08-11 2024-06-19 Sana Biotechnology, Inc. Genetically modified primary cells for allogeneic cell therapy
WO2023019227A1 (en) 2021-08-11 2023-02-16 Sana Biotechnology, Inc. Genetically modified cells for allogeneic cell therapy to reduce complement-mediated inflammatory reactions
JP2024534772A (en) 2021-08-11 2024-09-26 サナ バイオテクノロジー，インコーポレイテッド Genetically modified cells for allogeneic cell therapy
WO2023019225A2 (en) 2021-08-11 2023-02-16 Sana Biotechnology, Inc. Genetically modified cells for allogeneic cell therapy to reduce instant blood mediated inflammatory reactions
WO2023173123A1 (en) 2022-03-11 2023-09-14 Sana Biotechnology, Inc. Genetically modified cells and compositions and uses thereof
WO2023183313A1 (en) 2022-03-22 2023-09-28 Sana Biotechnology, Inc. Engineering cells with a transgene in b2m or ciita locus and associated compositions and methods
TW202440929A (en) 2022-12-14 2024-10-16 加拿大商普羅維登斯治療控股公司 Compositions and methods for infectious diseases
WO2024151541A1 (en) 2023-01-09 2024-07-18 Sana Biotechnology, Inc. Type-1 diabetes autoimmune mouse
WO2024229302A1 (en) 2023-05-03 2024-11-07 Sana Biotechnology, Inc. Methods of dosing and administration of engineered islet cells
WO2024243236A2 (en) 2023-05-22 2024-11-28 Sana Biotechnology, Inc. Methods of delivery of islet cells and related methods
WO2025043172A1 (en) 2023-08-23 2025-02-27 Sana Biotechnology, Inc. Modified cd47 proteins and their uses
WO2025166633A2 (en) 2024-02-07 2025-08-14 Westlake Genetech. Ltd. Split gene editing systems and uses thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0190254A4 (en) * 1984-07-05 1987-03-09 Genex Corp Cloned gene and method for making and using the same.
EP0218625B1 (en) * 1985-03-29 1995-04-05 Btg International Limited Infectious bronchitis virus spike protein
AU602875B2 (en) * 1985-12-18 1990-11-01 British Technology Group Limited Newcastle disease virus gene clones
WO1988002022A1 (en) * 1986-09-22 1988-03-24 Commonwealth Scientific And Industrial Research Or Recombinant poxviruses
EP0284416B1 (en) * 1987-03-27 1995-02-22 Nippon Zeon Co., Ltd. Recombinant avipoxyvirus
US5093258A (en) * 1988-08-26 1992-03-03 Therion Biologics Corporation Recombinant fowlpox virus and recombination vector

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7553831B2 (en) 2000-06-30 2009-06-30 Elan Pharmaceuticals, Inc. Compounds to treat Alzheimer's disease

Also Published As

Publication number Publication date
AU613291B2 (en) 1991-07-25
GB8724885D0 (en) 1987-11-25
EP0389509B1 (en) 1993-06-30
JPH03500604A (en) 1991-02-14
DE3882144T2 (en) 1993-10-07
AU2618088A (en) 1989-05-23
EP0389509A1 (en) 1990-10-03
GB2211504A (en) 1989-07-05
DE3882144D1 (en) 1993-08-05
US5182210A (en) 1993-01-26
WO1989003879A1 (en) 1989-05-05
GB8824746D0 (en) 1988-11-30

Similar Documents

Publication Publication Date Title
GB2211504B (en) Fowlpox virus promoters
AR241939A1 (en) Recombinant avipox virus
GB8714539D0 (en) Catalysts
GB8716653D0 (en) Silver-containing catalyst
PH25327A (en) Binfunctional proteins
GB8714661D0 (en) Catalysts
EP0378666A4 (en) Interleukin ii analogs
GB8722008D0 (en) Catalysts
GB8730131D0 (en) Catalysts
GB8923652D0 (en) Fowlpox virus promoter
GB2208629B (en) Stiffening means
AU96809S (en) Stapler
GB8713559D0 (en) Structural proteins
GB8917059D0 (en) Avipox virus promoters
GB8629739D0 (en) Bookbinding
GB8615353D0 (en) Interferon
GB8727379D0 (en) Catalysts
ZA897965B (en) Fowlpox virus promoter
GB8909043D0 (en) Fowlpox virus promoter
GB8710772D0 (en) Ready lights
ZA886415B (en) Recombinant avipox virus
GB8627260D0 (en) Stapler
GB8724421D0 (en) Catalysts
GB8716271D0 (en) Catalysts
GB8727510D0 (en) Catalysts

Legal Events

Date Code Title Description
732 Registration of transactions, instruments or events in the register (sect. 32/1977)
PCNP Patent ceased through non-payment of renewal fee

Effective date: 19951021